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Abstract
Anti-tumour necrosis factor (TNF)-a treatments are immuno-
suppressant and represent an important risk factor for develop-
ing infections. We report a case of Salmonella paratyphi
bacteraemia associated with soft tissue infection in a patient
who used inﬂiximab and had recently travelled to India. This
case report provides supporting evidence, essentially based only
on case reports, that patients receiving anti-TNF-a treatments
have an increased susceptibility to Salmonella infections, which
may develop at unusual and disseminated sites. We emphasize
the importance of appropriate counselling of patients undergoing
anti-TNF treatment and travelling to areas in which Salmonellae
are endemic, as well as the importance of advice to these
patients concerning food hygiene.
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Anti-tumour necrosis factor (TNF)-a therapies represent a
consolidated treatment in rheumatoid arthritis (RA) that is
associated with an important reduction in disease activity
and radiographic progression. Anti-TNF-a treatments are
immunosuppressant and represent an important risk factor
for developing infections as a result of intracellular bacterial
pathogens, such as Salmonellae and Mycobacteria, as well as
fungi [1]. This is because TNF-a is an essential component of
the host defences, both for the control of intracellular
pathogens and for granuloma formation and maintenance [2].
Salmonella paratyphi is a Gram-negative bacillus that causes
disease in humans only, and therefore it is most frequently
transmitted by ingestion of food or water contaminated with
human excreta. In immunocompromised patients, S. paratyphi
can demonstrate extraintestinal manifestations, such as infec-
tion of bone and soft tissues [3].
We report the case of a 54-year-old Caucasian man living
in the Genoa area, Italy, who was diagnosed with RA in
1981, and who subsequently received long-term treatment
with methotrexate (MTX) (7.5 mg weekly) and corticoster-
oids (5 mg prednisone daily). Because the patient was poorly
responsive to the combination of MTX and prednisone, an
anti-TNF-a treatment (inﬂiximab, 5 mg/kg)was introduced in
2007, with a rapid favourable clinical response. After 1 year
of inﬂiximab therapy, he travelled to India for 1 month. No
speciﬁc vaccinations or prophylaxis were prescribed. During
the time spent in India, he experienced an episode of acute
gastroenteritis, with apparent complete resolution after
3 days of rifamixin treatment. The exposure history was not
clear; however, the patient had consumed raw vegetables.
Immediately on his arrival in Italy, the patient took the anti-
TNF-a dose that he had postponed because of travelling.
Three weeks after the previous gastroenteritis episode, he
presented with excessive sweating and cough, followed by
intermittent daily fever (Tmax 38.5C). After 3 days, a soft tis-
sue infection involving the left arm became evident and he
was admitted to the hospital. MTX and inﬂiximab were
promptly stopped. Physical examination revealed important
signs of inﬂammation in his left arm. Laboratory analysis
showed elevated C-reactive protein (189 mg/L, normal value
<5.0), erythrocyte sedimentation rate (49 mm/h, nor-
mal £ 10) and white blood cell count (12 100/mL, with
10 900/mL neutrophilis). An abdominal ultrasonography
showed hepatomegaly and cholelithiasis. The microscopy and
culture of stool specimens at admission and during hospital-
ization were negative. An echocardiography did not reveal
any signs of endocarditis. Colour Doppler ultrasonography of
the left arm showed no alteration of the peripheral vasculari-
zation and chest radiography was negative. S. paratyphi group
A was isolated from four of four sets of blood cultures and
from a skin biopsy of the left arm lesion. Susceptibility tests
showed an MIC of 4 mg/L for ampicillin, 2 mg/L for cipro-
ﬂoxacin and <1 mg/L for ceftriaxone. Therapy was started
with intravenous ceftriaxone (2 g twice daily) and the
fever resolved promptly and blood cultures became
negative within 2 days. The soft tissue localization resolved
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completely within 1 week. The patient was discharged from
the hospital after 10 days, with no complications. To our
knowledge, this is the ﬁrst report of S. paratyphi bacteraemia
with soft tissue localization associated with the use of inﬂix-
imab, even though the concomitant use of other immunosup-
pressive agents (long-term MTX and corticosteroid-based
treatments) could have played a role in the development of
the S. paratyphi infection.
Dixon et al. [4] recently described the increased risk of
skin and soft tissue infections in patients treated with anti-
TNF-a drugs. Indeed, TNF-a has been shown to play a key
role in cutaneous immunity and inﬂammation not only by
recruitment of inﬂammatory cells to the skin, but also by
mobilization of cutaneous antigen-presenting cells (Langer-
hans cells) from the epidermis to draining lymph nodes [5,6].
The present case report provides supporting evidence,
essentially based only on case reports, that patients receiving
anti-TNF-a treatments have an increased susceptibility to Sal-
monella infections, which may develop at unusual and dissem-
inated localizations, because of the lack of an effective
inﬂammatory response. Other studies have reported similar
cases that were caused by different species of Salmonella in
patients receiving anti-TNF-a therapy [2,7–9] Epidemiologi-
cally, enteric fever continues to be a global health problem:
the disease is endemic in many developing countries, particu-
larly in the Indian subcontinent, South and Central America
and Africa [10]. An important characteristic of strains of Sal-
monella in developing countries is antimicrobial resistance,
most liekly promoted by the widespread use of antimicrobial
agents [10]. In developing countries, diagnostic tools are still
not generally available and this contributes to a lack of accu-
rate epidemiological and etiological data and promotes the
widespread use of empirical treatments, which all comprise
risk factors for the spread of resistant microorganisms. The
susceptibility test of the S. paratyphi isolates in the present
study revealed increased MICs of ampicillin and ciproﬂoxacin,
as reported in many developing countries [11]. We would
like to emphasize the importance of providing appropriate
counselling to immunocompromised patients travelling to
areas in which Salmonellae are endemic, as well as the impor-
tance of providing advice to these patients concerning food
hygiene. Makkuni et al. [12], who found that food-borne
infections derive from typical identiﬁable sources, empha-
sized the important role of advice concerning hygiene in
patients undergoing anti-TNF-a therapy. In our opinion, it is
important to explain to patients travelling to endemic areas
that S. paratyphi is transmitted by the ingestion of contami-
nated food, as typically sold by street vendors [13]. Particu-
larly, S. paratyphi can be spread through contaminated raw
eggs, unpasteurized milk and undercooked meat, which
should be avoided when travelling to endemic areas. Coun-
selling is particularly important considering that, at present,
neither of the two available vaccines provide protection
against S. paratyphi [11] and, consequently, no preventive
strategies for active immunization are available. The only
possible preventive strategy is the education of patients, in
association with their strict monitoring when they return
from trips to endemic areas.
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